# Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

Study · id `cardio:ct-nct02554890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02554890](<https://clinicaltrials.gov/study/NCT02554890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02554890

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 887 participants.

## Technical summary

Registry record NCT02554890. Randomized; quadruple masking; primary purpose supportive care. Start 2016-04-29 (actual); primary completion 2018-06-29 (actual). Results posted on 2019-09-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 887 participants (enrolled count; ClinicalTrials.gov record NCT02554890, source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)
- Started: 2016-04-29 (actual) (ClinicalTrials.gov record NCT02554890, source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)
- Primary completion: 2018-06-29 (actual) (ClinicalTrials.gov record NCT02554890, source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)
- Completion: 2018-07-24 (actual) (ClinicalTrials.gov record NCT02554890, source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)
- Results first posted: 2019-09-24 (ClinicalTrials.gov record NCT02554890, source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02554890, source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02554890-2021-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
- Acronym: PIONEER-HF
- Condition: Acute Heart Failure
- Intervention (Drug): sacubitril/valsartan (LCZ696)
- Intervention (Drug): Enalapril
- Intervention (Drug): sacubitril/valsartan (LCZ696) matching placebo
- Intervention (Drug): enalapril matching placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial (`cardio:pubmed-31825471`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists (`cardio:pubmed-32854838`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial (`cardio:pubmed-32800511`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial (`cardio:pubmed-32919915`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 492357b6362b7a9ebee07605eb471f59624936d381eda932c5ff1cc58282b20f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
